Robbins LLP announced that a securities class action has been filed on behalf of investors who acquired Fractyl Health, Inc. securities between January 13, 2025, and January 29, 2026. The complaint alleges that Fractyl and certain defendants overstated the efficacy and clinical, regulatory and commercial prospects of Revita, an outpatient therapy designed to modify duodenal dysfunction, and failed to disclose operational issues at one or more REMAIN-1 Midpoint Cohort sites. Fractyl reported on January 29, 2026, that Revita-treated patients experienced 4.5% weight regain after six months, compared with 7.5% in the sham arm, while noting that the cohort was not sufficiently powered for efficacy analysis. CEO defendant Harith Rajagopalan said one site had recorded higher-than-expected regain across both arms. Fractyl shares fell 68.03% to $0.585 that day, and Morgan Stanley later downgraded the stock and cut its price target to $2 from $8. The shares fell to $0.46 on January 30. Investors have until October 20, 2026, to seek appointment as lead plaintiff.